Tyler Menichiello
Tyler Menichiello is chief editor of Bioprocess Online, where he interviews biopharma executives and subject matter experts about the industry’s most pressing challenges. He aims to deliver actionable insights for biologics developers and manufacturers. Previously, he spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, working on clinical trials for hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can connect with Tyler on LinkedIn.
ARTICLES BY TYLER MENICHIELLO
-
![innovation-GettyImages-2155769551]( "AstraZeneca's Focus On Predictive Control, Semi-Autonomous Processing")
AstraZeneca's Focus On Predictive Control, Semi-Autonomous Processing9/30/2026This article captures key takeaways from a BioProcess International keynote by Preeya Boppana, director of MSAT process analytics and laboratories at AstraZeneca, titled “Transforming Biologics Manufacturing: Leveraging Predictive Analytics and Advanced Process Control for Next-Generation Operations.”
-
![quality control and precision in scientific research, quality assurance, laboratory work-GettyImages-2160759983]( "Prioritizing Quality Over Everything")
Prioritizing Quality Over Everything9/28/2026Regulatory compliance and cGMP manufacturing expert Tatyana Matveeva, Ph.D., explains the role and importance of a quality unit in an organization, as well as what happens when it’s compromised.
-
![switch it on-GettyImages-1226115595]( "Evaluating The Levers Driving Productivity In Bioprocessing")
Evaluating The Levers Driving Productivity In Bioprocessing8/28/2026Experts discuss where productivity gains can be achieved and how development teams should seek to improve process performance in this recap of the Bioprocess Online Live event "The Levers And Tradeoffs That Drive Process Productivity."
-
![growth chart-GettyImages-1491553346]( "Overcoming Recovery Challenges In AAV Production")
Overcoming Recovery Challenges In AAV Production8/26/2026Siren Biotechnology's SVP of vector development, Nathalie Clément, Ph.D., explains the challenge of purifying AAV capsids and the ways developers are optimizing vector recovery.
-
![puzzle 2 hands putting together-GettyImages-2162505342]( "Preserving Tacit Knowledge In ADC Tech Transfers")
Preserving Tacit Knowledge In ADC Tech Transfers8/19/2026ADCs built on proprietary platforms risk losing process-specific knowledge during a tech transfer. See what advice panelists from the Bioprocess Online Live event "Ensuring Successful Technology Transfer In ADC Development" shared with the audience on preserving this implicit knowledge.
-
-
![GettyImages-1490925234]( "Multispecific Manufacturability Starts With Molecular Design")
Multispecific Manufacturability Starts With Molecular Design7/21/2026AP Biosciences’ VP of antibody discovery, Jhong-Jhe You, Ph.D., explains the key design elements of multispecific antibodies and how they affect product developability.
-
![IMG_7262]( "On The Ground At BIO 2026: Johanna Kaufmann, Ph.D., On The Oncology Modality Puzzle")
On The Ground At BIO 2026: Johanna Kaufmann, Ph.D., On The Oncology Modality Puzzle7/10/2026At the 2026 BIO International Convention, Bioprocess Online caught up with Johanna Kaufmann, Ph.D., CSO at Deck Bio, a company developing multi-targeted T-cell engagers for solid tumors.
-
![IMG_7157]( "BIO 2026: Modernizing The FDA And Bolstering The Workforce")
BIO 2026: Modernizing The FDA And Bolstering The Workforce7/10/2026Bioprocess Online's chief editor, Tyler Menichiello, shares his key takeaways from the 2026 BIO International Convention in San Diego.
-
![Crowley Pic (1)]( "BIO 2026: Crowley On Competing With China And Modernizing The FDA")
BIO 2026: Crowley On Competing With China And Modernizing The FDA7/8/2026Exclusive coverage from John Crowley's press conference at the 2026 BIO International Convention in San Diego.
